| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |